2 completed. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Completed 2 |
Follow Mucosal Melanoma: new trials by email Literature Review of Mucosal Melanoma trials Research Report on Mucosal Melanoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery Carboplatin, Laboratory Biomarker Analysis, Paclitaxel - Mucosal Melanoma, Recurrent Melanoma | Phase 3 | Completed | National Cancer Institute (NCI) | 823 | 2005-06-01 | 2015-10-19 |
| Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patients With Melanoma That Has Been Removed By Surgery Laboratory Biomarker Analysis, Placebo, Sargramostim - Iris Melanoma, Medium/Large Size Posterior Uveal Melanoma | Phase 3 | Completed | National Cancer Institute (NCI) | 815 | 2000-02-23 | 2026-06-24 |
Melanoma (2) · Uveal Melanoma (1)
Neoplasms (2) · Neoplasms by Histologic Type (2) · Neoplasms by Site (2) · Neoplasms, Germ Cell and Embryonal (2) · Neoplasms, Nerve Tissue (2) · Neuroectodermal Tumors (2) · Neuroendocrine Tumors (2) · Nevi and Melanomas (2) · Skin Diseases (2) · Skin Neoplasms (2) · Skin and Connective Tissue Diseases (2) · Eye Diseases (1) · Eye Neoplasms (1) · Uveal Diseases (1) · Uveal Neoplasms (1)
Carboplatin (1) · Colony-Stimulating Factors (1) · Paclitaxel (1) · Sorafenib (1) · Taxes (1) · sargramostim (1)
National Cancer Institute (NCI) (2)
United States (2) · Australia (1)
David H Lawson (1) · Keith Flaherty (1)
U10CA021115 (2), U10CA180820 (1)